Free Trial
NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

Vertex Pharmaceuticals logo
$466.36 +6.95 (+1.51%)
Closing price 04:00 PM Eastern
Extended Trading
$460.60 -5.76 (-1.24%)
As of 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Vertex Pharmaceuticals Stock (NASDAQ:VRTX)

Key Stats

Today's Range
$456.77
$470.34
50-Day Range
$421.16
$509.50
52-Week Range
$377.85
$519.88
Volume
1.10 million shs
Average Volume
1.42 million shs
Market Capitalization
$119.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$511.62
Consensus Rating
Moderate Buy

Company Overview

Vertex Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
87th Percentile Overall Score

VRTX MarketRank™: 

Vertex Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 119th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 13 buy ratings, 14 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Vertex Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Vertex Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Vertex Pharmaceuticals are expected to grow by 12.03% in the coming year, from $15.63 to $17.51 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vertex Pharmaceuticals is -118.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vertex Pharmaceuticals is -118.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vertex Pharmaceuticals has a P/B Ratio of 7.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Vertex Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.57% of the float of Vertex Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vertex Pharmaceuticals has recently decreased by 8.62%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Vertex Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Vertex Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.57% of the float of Vertex Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vertex Pharmaceuticals has recently decreased by 8.62%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Vertex Pharmaceuticals has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 28 news articles for Vertex Pharmaceuticals this week, compared to 29 articles on an average week.
  • Search Interest

    31 people have searched for VRTX on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.
  • MarketBeat Follows

    18 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,084.00 in company stock.

  • Percentage Held by Insiders

    Only 0.20% of the stock of Vertex Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vertex Pharmaceuticals' insider trading history.
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Stock News Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
The Best Stocks to Invest $1,000 In Right Now
See More Headlines

VRTX Stock Analysis - Frequently Asked Questions

Vertex Pharmaceuticals' stock was trading at $402.70 at the start of the year. Since then, VRTX shares have increased by 15.8% and is now trading at $466.36.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings data on Monday, May, 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by $0.23. Vertex Pharmaceuticals's quarterly revenue was up 2.6% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of Vertex Pharmaceuticals: V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and others.

Top institutional shareholders of Vertex Pharmaceuticals include Atwood & Palmer Inc. (0.02%), Gradient Investments LLC (0.01%), LVM Capital Management Ltd. MI (0.01%) and E. Ohman J or Asset Management AB. Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Charles F Wagner Jr, Bruce I Sachs, Bastiano Sanna, David Altshuler, Carmen Bozic, Edward Morrow Atkinson III, Jonathan Biller, Jeffrey M Leiden, Kristen Ambrose, Joy Liu, Sangeeta N Bhatia and Yuchun Lee.
View institutional ownership trends
.

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include Salesforce (CRM), Chevron (CVX), QUALCOMM (QCOM), AbbVie (ABBV), Home Depot (HD), CocaCola (KO) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
5/05/2025
Today
7/08/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VRTX
Employees
6,100
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$511.62
High Stock Price Target
$586.00
Low Stock Price Target
$420.00
Potential Upside/Downside
+9.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.54
Research Coverage
28 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
29.90
P/E Growth
N/A
Net Income
-$535.60 million
Pretax Margin
-2.70%

Debt

Sales & Book Value

Annual Sales
$11.02 billion
Price / Cash Flow
N/A
Book Value
$63.72 per share
Price / Book
7.33

Miscellaneous

Free Float
256,283,000
Market Cap
$120.02 billion
Optionable
Optionable
Beta
0.41

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:VRTX) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners